Collectively, there is evidence that both GABA and GAD65 Alum interventions can alter the phenotype of Teff cells and inhibit the synthesis of some proinflammatory cytokines and chemokines from PBMCs of T1D patients. Here, GAD2 is linked to type 1 diabetes mellitus.